Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

Efficacy and Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared with Exenatide Twice Daily and Sitagliptin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

(2011) Nicole R Pinelli et al.   ANNALS OF PHARMACOTHERAPY

Clarifying the Role of Incretin-Based Therapies in the Treatment of Type 2 Diabetes Mellitus

(2011) R. Keith Campbell   CLINICAL THERAPEUTICS

Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia

(2011) B. Gallwitz et al.   DIABETES CARE

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus

(2011) C. Reasner et al.   DIABETES OBESITY & METABOLISM

Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs

(2011) K. R. Hjøllund et al.   DIABETOLOGIA

Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients

(2011) Giuseppe Derosa et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

GLP-1 for type 2 diabetes

(2011) Bo Ahrén   EXPERIMENTAL CELL RESEARCH

Incretin-based therapies - review of the physiology, pharmacology and emerging clinical experience

(2011) J. H. Martin et al.   INTERNAL MEDICINE JOURNAL

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

(2011) Thomas Blevins et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications

(2010) Michael A. Nauck   AMERICAN JOURNAL OF MEDICINE

Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1

(2010) E M Migoya et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effects of Exenatide Plus Rosiglitazone on  -Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

(2010) R. A. DeFronzo et al.   DIABETES CARE

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial

(2010) R. Arechavaleta et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2010) M.-R. Taskinen et al.   DIABETES OBESITY & METABOLISM

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl

(2010) W. Yang et al.   DIABETES OBESITY & METABOLISM

Exenatide Versus Glibenclamide in Patients with Diabetes

(2010) G. Derosa et al.   Diabetes Technology & Therapeutics

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

(2010) André J. Scheen et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

(2010) A. Maida et al.   DIABETOLOGIA

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

(2010) Richard M Bergenstal et al.   LANCET

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

(2010) Debora Williams-Herman et al.   BMC Endocrine Disorders

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

(2010) Bo Ahren   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

(2009) R. A. DeFronzo et al.   DIABETES CARE

Efficacy and Tolerability of Vildagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy

(2009) M. Goodman et al.   HORMONE AND METABOLIC RESEARCH

Efficacy and safety of incretin-based therapies: Clinical trial data

(2009) John White   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Incretin-based therapies for type 2 diabetes mellitus

(2009) Julie A. Lovshin et al.   Nature Reviews Endocrinology

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

(2008) Itamar Raz et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*

(2008) R. Scott et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

(2008) M. A. Nauck et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE